AU2022405604A1 - Compositions and methods for oral administration - Google Patents

Compositions and methods for oral administration Download PDF

Info

Publication number
AU2022405604A1
AU2022405604A1 AU2022405604A AU2022405604A AU2022405604A1 AU 2022405604 A1 AU2022405604 A1 AU 2022405604A1 AU 2022405604 A AU2022405604 A AU 2022405604A AU 2022405604 A AU2022405604 A AU 2022405604A AU 2022405604 A1 AU2022405604 A1 AU 2022405604A1
Authority
AU
Australia
Prior art keywords
polypeptide
polypeptide construct
construct
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022405604A
Other languages
English (en)
Other versions
AU2022405604A2 (en
Inventor
Jonathan POLLETT
Ngoc THAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imagine Pharma LLC
Original Assignee
Imagine Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma LLC filed Critical Imagine Pharma LLC
Publication of AU2022405604A1 publication Critical patent/AU2022405604A1/en
Publication of AU2022405604A2 publication Critical patent/AU2022405604A2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
AU2022405604A 2021-12-11 2022-12-09 Compositions and methods for oral administration Pending AU2022405604A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288579P 2021-12-11 2021-12-11
US63/288,579 2021-12-11
PCT/US2022/081277 WO2023108126A1 (en) 2021-12-11 2022-12-09 Compositions and methods for oral administration

Publications (2)

Publication Number Publication Date
AU2022405604A1 true AU2022405604A1 (en) 2024-06-13
AU2022405604A2 AU2022405604A2 (en) 2024-07-11

Family

ID=86731317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022405604A Pending AU2022405604A1 (en) 2021-12-11 2022-12-09 Compositions and methods for oral administration

Country Status (11)

Country Link
US (1) US20250388638A1 (https=)
EP (1) EP4444352A4 (https=)
JP (1) JP2024545981A (https=)
KR (1) KR20240141165A (https=)
CN (1) CN118613284A (https=)
AU (1) AU2022405604A1 (https=)
CA (1) CA3235948A1 (https=)
IL (1) IL312382A (https=)
MX (1) MX2024007105A (https=)
WO (1) WO2023108126A1 (https=)
ZA (1) ZA202404443B (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
KR100944034B1 (ko) * 2007-04-19 2010-02-24 한올제약주식회사 프로테아제-내성 폴리펩티드의 경구 투여 제형
KR102497242B1 (ko) * 2016-11-13 2023-02-09 이매진 파마 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법
PL3746111T3 (pl) * 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową

Also Published As

Publication number Publication date
WO2023108126A9 (en) 2023-08-24
CA3235948A1 (en) 2023-06-15
MX2024007105A (es) 2024-06-24
EP4444352A4 (en) 2025-12-17
KR20240141165A (ko) 2024-09-25
WO2023108126A1 (en) 2023-06-15
AU2022405604A2 (en) 2024-07-11
IL312382A (en) 2024-06-01
JP2024545981A (ja) 2024-12-17
ZA202404443B (en) 2025-10-29
US20250388638A1 (en) 2025-12-25
CN118613284A (zh) 2024-09-06
EP4444352A1 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
US9074015B2 (en) Recombinantly expressed insulin polypeptides and uses thereof
CN101389650B (zh) 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP5749155B2 (ja) プロテアーゼ安定化アシル化インスリンアナログ
JP2019038812A (ja) ゴナドトロピンカルボキシ末端ペプチドに結合することによりポリペプチドの流体力学的体積を増加させる方法
JP2003160598A (ja) 接合安定化されたポリペプチド組成物
CN104010650A (zh) 长效生长激素及其生产方法
KR20150121715A (ko) Ｃｓｆ１ 치료제
MX2010011845A (es) Agonistas del receptor y2 y/o y4 de larga accion.
WO2021034728A1 (en) Compositions and particles for payload delivery
Lee et al. Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity
EP3442562B1 (en) An il-22 dimer for use in treating necrotizing enterocolitis
WO2021037187A1 (zh) 一种多肽及其应用
US20250388638A1 (en) Compositions and methods for oral delivery
US7671015B2 (en) Aequorin-containing compositions and methods of using same
HK40109249A (zh) 用於口服给予的组合物和方法
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
TW202535451A (zh) 經修飾之調酸素及其使用方法
HK40002973B (en) An il-22 dimer for use in treating necrotizing enterocolitis
HK40002973A (en) An il-22 dimer for use in treating necrotizing enterocolitis
NZ622174A (en) Glucagon-like peptide-2 compositions and methods of making and using same
JPWO2023108126A5 (https=)